Table 4 The m6A-modified ncRNAs in different cancers.
From: The role of N6-methyladenosine-modified non-coding RNAs in the pathological process of human cancer
Cancer | NcRNAs | M6A Enzyme | Mechanism | Roles | References (PMID) |
|---|---|---|---|---|---|
Lung cancer | LCAT3 | METTL3 | METTL3 increases the stability of LCAT3, which activates MYC transcription | M6A-modified lncRNA LCAT3 promotes proliferation, survival, invasion and metastasis of lung cancer cells | 34274028 |
circNDUFB2 | IGF2BPs | M6A-modified circNDUFB2 enhances the interaction between TRIM25 and IGF2BPs, which facilitates ubiquitination degradation of IGF2BPs | M6A-modified circNDUFB2 inhibits growth and metastasis of NSCLC cells | 33436560 | |
circIGF2BP3 | METTL3 YTHDC1 | M6A modification promotes circularization of circIGF2BP3, which upregulates PKP3 to compromise the cancer immune response | CircIGF2BP3/PKP3 inhibits the immune therapy efficacy in lung carcinoma mouse model | 34416901 | |
miR-143-3p | METTL3 | M6A modification promotes the splicing of precursor miR-143-3p to mature miR-143-3p | MiR-143-3p is a poor prognostic factor of cancer. | 31823788 | |
Hepatocellular carcinoma | MEG3 | METTL3 | M6A modification decreases the stability of MEG3 | MEG3 inhibits the proliferation, migration and invasion of HCC cells | 34163177 |
LINC00958 | METTL3 | M6A modification increases the stability of LINC00958 | LINC00958 promotes HCC malignant phenotypes in vivo and in vitro | 31915027 | |
Glioma | MALAT1 | METTL3 | M6A modification increases the stability of MALAT1 | M6A modification upregulates MALAT1 to activate NF-κB, which facilitates the malignant phenotypes of IDH-wildtype gliomas | 33933553 |
Gastric cancer | ThAP7-AS1 | METTL3 IGF2BP1 | M6A modification increases the expression of ThAP7-AS1 | HAP7-AS1 was correlated with positive lymph node metastasis and poorer prognosis in gastric cancer | 34608273 |
LINC01320 | METTL14 | M6A modification increases the expression of LINC01320 | LINC01320 facilitates the malignant phenotypes of gastric cancer cells via regulating the miR-495-5p/RAB19 signal pathway | 34288797 | |
miR-17-92 | METTL3 | M6A modification promotes the splicing of pri-miR-17-92 to mature miR-17-92 | M6A-modified miR-17-92 increases sensitivity of gastric cancer to everolimus | 33037176 | |
Brest cancer | 18 S rRNA | METTL5 | M6A modification promotes 18 S rRNA binding to mRNA by inducing conformation changes in ribosomal decoding center | M6A-modified 18 S rRNA facilitates translation initiation and cell growth in breast cancer | 33357433 |
LINC00958 | METTL3 | M6A modification increases the stability of LINC00958 | M6A-mediated upregulation of LINC00958 facilitates the malignant phenotypes of BC cells | 33531456 | |
circMETTL3 | METTL3 | M6A modification increases the expression of circMETTL3 | M6A-mediated upregulation of circMETTL3 facilitates the malignant phenotypes of BC cells | 33867838 | |
Colorectal cancer | miR-1246 | METTL3 | M6A modification promotes the splicing of pri-miR-1246 to mature miR-1246 | M6A-modified pri-miR-1246 facilitates metastasis of colorectal cancer | 31492150 |
miR-375 | METTL14 | M6A modification promotes the splicing of pri-miR-375 to mature miR-375 | M6A-modified pri-miR-375 inhibits growth, migration, and invasion of colorectal cancer cell | 31839484 | |
circ1662 | METTL3 | M6A modification promotes circ1662 expression | M6A-modified circ1662 facilitates metastasis of colorectal cancer | 33754062 | |
LBX2-AS1 | METTL3 | M6A modification increases the expression of LBX2-AS1 | M6A-modified LBX2-AS1 facilitates colorectal cancer progression and chemotherapy resistance | 34535128 |
